A detailed history of Relyea Zuckerberg Hanson LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Relyea Zuckerberg Hanson LLC holds 2,710 shares of LLY stock, worth $2.08 Million. This represents 0.37% of its overall portfolio holdings.

Number of Shares
2,710
Previous 2,642 2.57%
Holding current value
$2.08 Million
Previous $2.39 Million 0.33%
% of portfolio
0.37%
Previous 0.4%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$772.14 - $960.02 $52,505 - $65,281
68 Added 2.57%
2,710 $2.4 Million
Q2 2024

Oct 31, 2024

BUY
$724.87 - $909.04 $121,053 - $151,809
167 Added 6.75%
2,642 $2.39 Million
Q2 2024

Jul 17, 2024

BUY
$724.87 - $909.04 $121,053 - $151,809
167 Added 6.75%
2,642 $2.39 Million
Q1 2024

Oct 31, 2024

BUY
$592.2 - $792.28 $58,035 - $77,643
98 Added 4.12%
2,475 $1.93 Million
Q1 2024

Apr 22, 2024

BUY
$592.2 - $792.28 $58,035 - $77,643
98 Added 4.12%
2,475 $1.93 Million
Q4 2023

Oct 31, 2024

BUY
$525.19 - $619.13 $2,100 - $2,476
4 Added 0.17%
2,377 $1.39 Million
Q4 2023

Jan 18, 2024

BUY
$525.19 - $619.13 $2,100 - $2,476
4 Added 0.17%
2,377 $1.39 Million
Q3 2023

Oct 31, 2024

SELL
$434.7 - $599.3 $146,493 - $201,964
-337 Reduced 12.44%
2,373 $1.27 Million
Q3 2023

Oct 16, 2023

BUY
$434.7 - $599.3 $231,260 - $318,827
532 Added 28.9%
2,373 $1.27 Million
Q2 2023

Jul 17, 2023

BUY
$350.74 - $468.98 $121,356 - $162,267
346 Added 23.14%
1,841 $863,000
Q1 2023

Apr 18, 2023

BUY
$310.63 - $364.82 $18,327 - $21,524
59 Added 4.11%
1,495 $513,000
Q4 2022

Jan 18, 2023

BUY
$321.55 - $374.67 $197,431 - $230,047
614 Added 74.7%
1,436 $0
Q3 2022

Nov 02, 2022

BUY
$296.48 - $337.87 $26,979 - $30,746
91 Added 12.45%
822 $266,000
Q2 2022

Jul 18, 2022

BUY
$278.73 - $327.27 $203,751 - $239,234
731 New
731 $237,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $730B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Relyea Zuckerberg Hanson LLC Portfolio

Follow Relyea Zuckerberg Hanson LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Relyea Zuckerberg Hanson LLC, based on Form 13F filings with the SEC.

News

Stay updated on Relyea Zuckerberg Hanson LLC with notifications on news.